The federal settlement resolves allegations of unlawful controlled substance prescribing and absent patient records and restricts future DEA registration for certain controlled substances.
To address allegations against Dr. Twan Phanijphand for unlawful prescribing of controlled substances.
Approach:
Allegations: Federal authorities alleged unlawful prescribing of at least 127 controlled substance prescriptions and failure to maintain patient records.
Settlement Details: Dr. Phanijphand reached a $300,000 civil settlement with the federal government regarding these allegations.
Controlled Substances Involved: Prescriptions included oxycodone-acetaminophen, hydrocodone-acetaminophen, lorazepam, alprazolam, clonazepam, and tramadol.
DEA Registration: Phanijphand voluntarily surrendered his DEA registration on April 22, 2026, and agreed not to reapply for certain controlled substances.
Future Compliance: He must complete continuing medical education in controlled substance prescribing and recordkeeping, and undergo additional DEA monitoring.
Key Findings:
Allegations involved unlawful prescribing under the Controlled Substances Act.
Settlement amount was $300,000.
Phanijphand prescribed multiple controlled substances without maintaining required records.
Interpretation:
The settlement does not imply an admission of liability by Dr. Phanijphand, nor does it concede the validity of the federal claims.
Limitations:
Details on the specific circumstances of the alleged unlawful prescribing were not provided.
The settlement does not include an admission of wrongdoing.
Conclusion:
The case highlights the importance of compliance with the Controlled Substances Act regarding recordkeeping and prescribing practices.
